Alto Neuroscience bags new US patent for depression drug ALTO-207

ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease

China nod to two Sanofi drugs for rare and complex conditions

Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM

Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early

Over 8.8?million Indians aged 60 and above currently live with dementia,

Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation

Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy

Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer

The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer

Redesigned brain receptor drugs show promise for depression

The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold

Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment

UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation

Vetter advances next-gen syringe closure system towards 2027 launch

The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats

BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company

FDA endorses Relmada’s registrational strategy for bladder cancer therapy